Atsou et al – IMPROVED CARE-PATHWAY CAN INCREASE THE OVERALL SURVIVAL AMONG ACUTE MYELOID LEUKAEMIA PATIENTS: A POPULATION-BASED STUDY USING DOUBLY ROBUST CAUSAL INFERENCE METHODS – GRELL 2024 Lausanne
Poster-GRELL_Lausanne_VFBACKGROUND
Approximately 10% of Acute Myeloid Leukaemia (AML) patients not admitted to a Specialized Haematology Unit (SHU) experienced a significant loss of therapeutic opportunity. We aim to determine the causal relationship between access to SHU and patient 1-year overall survival.
METHODS
Study population: 1039 AML-incidents cases diagnosed between 2012 and 2016 in Côte-d’Or, Gironde and Basse-Normandie department. Statistical analysis: We employed TMLE (Target Maximum Likelihood Estimation) with “Super-Learner” algorithm to estimate the adjusted Average Treatment Effect (ATE) of access to SHU, on patient overall survival, and derived the number of avoidable deaths attributable to access to SHU.
CONCLUSION
Admitting AML patients to a SHU during their care pathway could potentially mitigate the loss of therapeutic opportunities observed among non-SHU patients. This, in turn, might reduce the number of avoidable deaths causally attributable to the care pathway